KEYNOTE-189: chemo plus pembrolizumab for NSCLC

The KEYNOTE-189 ( NCT02578680) trial investigated the effects of adding pembrolizumab to cisplatin and pemetrexed in patients with non-small cell lung cancer (NSCLC). Here, Marina Garassino, MD, of th... Author: VJOncology Added: 07/31/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts